OKYO vs. KYTX, NMRA, SOPH, HUMA, VYGR, TKNO, ABEO, ALLO, PBYI, and CABA
Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Kyverna Therapeutics (KYTX), Neumora Therapeutics (NMRA), SOPHiA GENETICS (SOPH), Humacyte (HUMA), Voyager Therapeutics (VYGR), Alpha Teknova (TKNO), Abeona Therapeutics (ABEO), Allogene Therapeutics (ALLO), Puma Biotechnology (PBYI), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.
OKYO Pharma vs. Its Competitors
OKYO Pharma (NASDAQ:OKYO) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.
3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
OKYO Pharma currently has a consensus target price of $7.00, indicating a potential upside of 238.16%. Kyverna Therapeutics has a consensus target price of $19.00, indicating a potential upside of 161.71%. Given OKYO Pharma's higher probable upside, research analysts plainly believe OKYO Pharma is more favorable than Kyverna Therapeutics.
OKYO Pharma has higher earnings, but lower revenue than Kyverna Therapeutics.
OKYO Pharma has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.72, meaning that its share price is 272% more volatile than the S&P 500.
OKYO Pharma's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.
In the previous week, Kyverna Therapeutics had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 3 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.83 beat Kyverna Therapeutics' score of 0.46 indicating that OKYO Pharma is being referred to more favorably in the media.
Summary
OKYO Pharma and Kyverna Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get OKYO Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OKYO Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:OKYO) was last updated on 10/16/2025 by MarketBeat.com Staff
